Enhanced phagocytosis and cytotoxicity of co-activated FcRγ-BAI1/FcRγ-MERTK dual-CAR monocytes drive potent anti-solid tumor activity
Year: 2026
Type: article
Abstract: Chimeric antigen receptor macrophages (CAR-M) display superior tumor infiltration compared with CAR-T cells for solid tumor therapy, yet limited antitumor potency and antigen heterogeneity hinder their application. Direct engineering of chimeric antigen receptor monocytes (CAR-Mo) offers a simplified, cost-effective manufacturing alternative. Here, we engineered THP-1-derived monocytic cells with chimeric receptors containing FcRγ fused to phagocytosis-related cytoplasmic domains, targeting nucleolin and HER2. We constructed single-target and dual-antigen CAR-Mo platforms and evaluated their antitumor activity in vitro and in vivo . THP-1 monocytes carrying FcRγ-BAI1 or FcRγ-MERTK receptors exhibited enhanced phagocytosis, and dual-CAR-Mo achieved broader and stronger tumoricidal effects by targeting two tumor antigens. This dual-antigen-targeted CAR-Mo strategy activates both phagocytic and cytotoxic signaling pathways and represents a promising approach for solid tumor treatment. Collectively, this dual-target CAR-Mo strategy demonstrates promising antitumor efficacy in the THP-1 cell model, providing a feasible prototype for future optimization of solid tumor immunotherapy.
Source: iScience
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,240
Award: G885406935
OpenAlex ID: W7226003100
